Pfizer's Ibrance drug slows progression of breast cancer

Yahoo NewsPfizer's Ibrance drug slows progression of breast cancerReutersAt the time of an interim analysis, patients given Ibrance and AstraZeneca Plc's Faslodex (fulvestrant), a widely used treatment to block estrogen, lived an average of 9.2 months before their cancer worsened. This compared with 3.8 months for patients ...Drug boosts long-term survival after breast cancer: studyYahoo NewsCombo therapies effective in forms of leukemia, lymphoma and breast cancerWashington PostStudy finds safer drug to prevent return of breast cancerPittsburgh Post-GazetteBloomberg -Newsmaxall 65 news articles »

Share this post